Due to the inherent instability of RNA, safely and accurately delivering it to target tissues is crucial for the success of RNA vaccines and therapies.
However, conventional delivery technologies face two major bottlenecks:
Stringent Storage Conditions: They typically require ultra-low temperatures (e.g., -60°C) freezing for transportation and storage, and require prolonged thawing before use, which severely limits their use in regions with underdeveloped medical infrastructure.
Natural Liver Tropism: RNA drugs tend to accumulate predominantly in the liver, which restricts their therapeutic potential for non-liver diseases.
To overcome these fundamental limitations, we have independently developed two innovative delivery systems: 

Ready-to-Use (RTU) Delivery System 

Our proprietary Ready-to-Use (RTU) delivery system represents a significant breakthrough in thermal stability, providing superior storage conditions for various RNA vaccines compared to conventional technologies. 

Compared to traditional lipid nanoparticle (LNP) technology, the RTU delivery system demonstrates exceptional stability, maintaining stability for over 18 months in conventional refrigeration (2–8°C) and even maintaining long-term stability at room.

This breakthrough not only significantly reduces the overall costs and logistical barriers across the entire vaccine supply chain—from production and transportation to distribution—but also enables advance manufacturing and strategic stockpiling, allowing for rapid deployment during public health emergencies such as outbreaks.

Meanwhile, the RTU delivery system can effectively adsorb RNA payloads, providing effective protection and efficient delivery of RNA. It demonstrates comparable safety and efficacy to conventional delivery technologies. 

This stable, versatile, and cost-effective platform technology can be utilized with mRNA or srRNA encoding any antigen to generat highly adaptable vaccine candidates, greatly expanding the application prospects of RNA vaccines.

We have evaluated the safety and efficacy of our RTU delivery system in hundreds of clinical trial participants across programs such as JCXH-105 and JCXH-108.
Multiple patents for this delivery system have been granted in China and overseas, comprehensively covering its core components, formulation design, and applications, with additional patent applications continuously being filed in more countries and regions. 

Target Lipid Complex Nanoparticles (tLCNP) Delivery Systems 

Our proprietary tLCNP (targeted Lipid Complex Nanoparticle) delivery system is designed to overcome the liver-targeting limitations of conventional LNP technology, paving a new path for precisely delivering therapeutic agents to specific organs. 

We currently have two distinct tLCNP delivery systems: 

Lung-Targeting System: This system achieves at least 80% lung enrichment across multiple animal models and is preferentially taken up by endothelial and epithelial cells, which are the primary sites of lung cancer development. It demonstrates favorable safety upon repeated administrations, offering a versatile therapeutic tool for lung diseases such as lung cancer.

Spleen-Targeting System: This system demonstrates high efficiency in spleenspecific enrichment and successfully transfects key human immune cells, such as T cells, NK cells, and macrophages. It has been applied in our clinical-stage in vivo CAR programs.

We have filed international patent applications for these innovative tLCNP formulations to strengthen our leading position in the field of organ- and tissue-targeted RNA delivery.